Table 1. Baseline demographic and clinical data for patients.
| Ergocalciferol (n = 20) | Placebo (n = 18) | p value | |
| Age years | 45.8 (10.0) | 48.8 (12.2) | 0.39 |
| Sex (% male) | 14 (60.9%) | 14 (73.7%) | 0.22 |
| Body mass index | 30.4 (7.1) | 29.2 (3.4) | 0.51 |
| Ethnicity | 0.57 | ||
| Caucasian | 5 (21.8%) | 6 (31.6%) | |
| Non-Caucasian | 15 (78.2%) | 12 (68.4%) | |
| Cause of CKD | 0.74 | ||
| Hypertension | 5 (25%) | 7 (38.9%) | |
| Glomerulonephritis | 8 (40%) | 5 (27.8%) | |
| ADPKD | 2 (10%) | 1 (5.6%) | |
| Other ∼ | 5 (25%) | 5 (27.7%) | |
| Smoking status | 0.59 | ||
| Current smoker | 1 (5%) | 2 (11.1%) | |
| Never/Ex-smoker | 19 (95%) | 16 (88.9%) | |
| Presence of endovascular stent devices | 0 (0%) | 1 (5.6%) | 0.47 |
| ACE-I/ARB | 16 (80%) | 12 (66.7%) | 0.33 |
| β Blocker | 7 (35%) | 6 (33.3%) | 0.57 |
| Statin use | 9 (45%) | 7 (38.9%) | 0.84 |
| Anti platelet therapy | 2 (10%) | 3 (16.7%) | 0.48 |
| Folic acid | 1 (5.0%) | 1 (5.6%) | 1.00 |
| Nitrate containing medications # | 0 (0%) | 0 (0%) | 1.00 |
| Medications containing Vitamin D | 0 (0%) | 0 (0%) | 1.00 |
| BP in past history | 15 (65.2%) | 11 (57.9%) | 0.63 |
| Systolic BP (mmHg) | 114 (10) | 119 (10) | 0.11 |
| Diastolic BP (mmHg) | 70 (8) | 71 (7) | 0.57 |
| MAP (mmHg) | 84 (8) | 87 (8) | 0.29 |
| Pulse pressure (mmHg) | 45 (7) | 48 (6) | 0.08 |
| aPWV (m/s) | 8.5 (1.1) | 8.5 (1.5) | 0.66 |
| LVMI (g/m2) | 96.1 (36.3) | 87.5 (174) | 0.55 |
| Skin AF (AU) | 2.8 (0.9) | 3.1 (0.9) | 0.26 |
| FCD (mm-1) | 5.2 (0.5) | 5.0 (0.5) | 0.78 |
| MFI (AU) | 2.5 (0.1) | 2.4 (0.1) | 0.54 |
Figures in brackets are standard deviation of the mean or % of total in treatment group. ADPKD – autosomal dominant polycystic kidney disease. BP = blood pressure, ACE-I angiotensin converting enzyme inhibitor, ARB – angiotensin receptor blocker, MAP = mean arterial pressure, aPWV = aortic pulse wave velocity, LVMI – left ventricular mass index, AF – auto fluorescence, FCD – functional capillary density, MFI – microvascular flow index. AU – arbitrary units
- any form of glyceryl trinitrate, isosorbide mononitrate, isosorbide dinitrate or other esters of nitric acid
- Additional causes of CKD in ergocalciferol group: tubulo-interstitial nephritis (n = 1), reflux nephropathy (n = 2), unknown (n = 2). Placebo group: reflux nephropathy (n = 2), ischaemic nephropathy presumed due to reno-vascular disease (n = 1), unknown (n = 2).